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Tumor lysis syndrome (TLS) is an oncologic emergency that is caused by massive tumor cell lysis. It is commonly associated
with hematological cancers like leukemia and lymphoma and uncommonly with solid nonhematologic tumors as well. However,
spontaneous tumor lysis syndrome (STLS) without any cytotoxic chemotherapy rarely occurs in solid tumors. We describe a case
of STLS in a metastatic adenocarcinoma of unknown primary and review the literature of STLS in solid non-hematologic tumors
to identify various risk factors for pathogenesis of this entity.
1.CaseReport
A 59-year-old Caucasian female with past medical history of
hypertension, obesity, mild osteopenia, and >20 pack years
smokinghistorypresentedtotheprimarycarephysicianwith
a more than four-month history of generalized weakness,
anorexia, weight loss of more than 30 pounds, a growing
subcutaneous mass in the right lower back and back pain in
thelumbarregion.MRIofthespinerevealedconﬂuentbulky
soft tissue mass measuring approximately 14cm anteropos-
terior × 13cm transverse in size in the retroperitoneum
region and pathological compression fracture of L1 verte-
brae. Further, CT scan of chest/abdomen/pelvis conﬁrmed
bulky retroperitoneal mass/adenopathy with extensive liver
metastases and multiple tiny pulmonary nodules (Figure 1).
T h em a s sa tl o w e rb a c kw a se x c i s e da n di m m u n o h i s -
tochemical staining of subcutaneous mass was positive for
cytokeratin 7, cytokeratin 20, mucicarmine and villin but
negative for ER, mammaglobin, TTF-1, napsin A, CDX2,
p63, calretinin, and hepatocyte antigen. The villin positivity
in conjunction with the cytokeratin 7 positive expression is
suggestive of a noncolorectal gastrointestinal origin, includ-
ing pancreaticobiliary/gallbladder source. The tissue of ori-
gin assay was unable to locate the primary source and sub-
sequently,diagnosisofpoorlydiﬀerentiatedadenocarcinoma
of unknown primary was rendered. Ten days after the biopsy,
while waiting for chemotherapy to begin, patient presented
to her primary care physician with severe nausea and vomit-
ing, altered mental status and decreased urine output. Basic
metabolic panel (Chem-7) was consistent with dehydration
with blood urea nitrogen (BUN) and creatinine of 31mg/dL
and 1.6mg/dL, respectively, elevated from her baseline
normal values about 10 days later. Patient was given a liter of
intravenous ﬂuid and was sent back home with antiemetics.
Four days later, after nausea and vomiting persisted with
lethargy, weakness and very poor appetite, patient presented
to emergency room. Chem-7 revealed BUN of 117mg/dL
with a creatinine of 7.5mg/dL. Other pertinent lab values
with normal values in parentheses showed calcium 6.5 (8.9–
10.3) mg/dL, phosphorus 8.8 (2.6–4.6) mg/dL, uric acid
26.5 (2.8–6.6) mg/dL, and lactate dehydrogenase 1265IU/L
with normal transaminases. Obstructive uropathy was
excluded by retroperitoneal ultrasound. Patient went into
oliguric acute renal failure (ARF) and was treated with intra-
venous ﬂuids. However, renal function did not improve over
the next two days, and hemodialysis was started along with
rasburicase. Lab abnormalities were consistent with TLS.
Due to poor prognosis, patient was not started on chemo-
therapy and discharged to hospice without chemotherapy,
and she died three weeks later.2 Case Reports in Medicine
Figure 1: Computed tomography of abdomen showing a big
retroperitoneal mass engulﬁng the vascular structures in the
abdomen.
2. Discussion
Tumor lysis syndrome (TLS) is an oncologic emergency that
is caused by massive tumor cell lysis with the release of large
amounts of potassium, phosphate, and nucleic acids into
the systemic circulation. The Cairo-Bishop deﬁnition of TLS
[1], proposed in 2004, provided both clinical and laboratory
diagnostic and grading criteria for TLS as per below:
(i) laboratory TLS is deﬁned as either a 25% change or
level above or below normal for any two or more
serum values of uric acid, potassium, phosphate, and
calcium within 3 days before or 7 days after the
initiation of chemotherapy in the setting of adequate
hydration and without use of any uricosuric agent;
(ii) clinical TLS is deﬁned as laboratory TLS plus one or
more of the following that was not directly attributed
to a therapeutic agent: increased serum creatinine
(≥1.5 times the upper limit of the normal, cardiac
arrhythmia/sudden death, or a seizure);
TLS most often occurs after the initiation of cytotoxic
therapyinpatientswithhigh-gradelymphomas(particularly
the Burkitt subtype) and acute lymphoblastic leukemia. TLS
has been rarely described after treatment of nonhematologic
solid tumors including breast cancer, germ cell tumors
[2], small-cell carcinoma (mostly involving the lung) [2,
3], medulloblastoma [2], sarcoma [2], metastatic colorectal
cancer, gastrointestinal stromal tumors, melanoma [2],
hepatocellular carcinoma [2], and other solid tumors as well.
TLS has been shown to occur spontaneously without any
cytotoxic therapy in hematologic cancers; however, it is very
rare to ﬁnd spontaneous tumor lysis syndrome (STLS) in
solid tumors. The extensive search of Pubmed for STLS
in non-hematologic solid tumors yielded 15 case reports
including our case report (Table 1).
We believe that our case had STLS because of evidence
of necrosis in the tumor and was probably precipitated by
the dehydration aggravated due to nausea and vomiting. We
excluded other causes for ARF, such as postrenal obstruction
(by ultrasound and CT scan), urinary tract infection (uri-
nalysis was normal for WBCs), parenchymal kidney disease
(which does not develop so quickly and renal parenchyma
appeared morphologically normal on ultrasound and CT
scan). Elevated serum uric acid is present in acute renal fail-
ure of any cause, especially in prerenal azotemia, but values
are generally below <15mg/dL except in TLS. In our patient,
serum uric acid >25mg/dL was again consistent with TLS.
The typical laboratory ﬁndings in outpatient such as hyper-
uricemia, hyperkalemia, hypocalcemia, hyperphosphatemia,
and ARF met the laboratory and clinical criteria of TLS.
According to TLS expert panel guidelines [15], most
solid tumors are classiﬁed as low risk for TLS, whereas
tumors which are sensitive to chemotherapy or have high-
proliferative index, such as neuroblastomas, germ cell, and
small-cell lung cancers, are classiﬁed as intermediate risk.
One-third of cases in Table 1 belonged to this intermediate
riskgroup, notablygermcelltumors [4,5,10],coherentwith
the fact that highly proliferative tumors have more tendency
to form large masses and presents with signiﬁcant tumor
burden oﬀering them a more likelihood to induce STLS.
The risk factors for STLS in solid tumors, based on the
review of literature and these case reports, include chemo-
therapy sensitive or high proliferative index tumors, tumor
burden, presence of liver and bone metastasis, abnormal
lab values including elevated serum uric acid, serum LDH,
and concomitant presence of risk factors for renal failure.
The most important risk factor was the tumor burden with
every report documenting stage 4 cancers having extensive
liver and bony metastases and presence of big-sized masses
(>10cm), which bestow them high predilection to undergo
autonecrosis releasing intracellular contents. The biopsy in
most of the cases revealed necrotic tissue in the center of the
massesaswellasinliverandbonemetastases.Themetastases
in liver and bone compared to an abdominal mass are at
higher risk to undergo ischemic central auto-necrosis due to
pressure induced by surrounding normal parenchyma on a
fastgrowingtumor,whereas,anintra-abdominalmasslikein
retroperitoneal region can grow to a signiﬁcant size without
lysis.
Another important risk factor would be preexistent
impaired renal function that can be further compromised
with the progression of the syndrome. The renal function
deterioration can lead to deﬁcient clearance of elevated uric
acid produced by tumor lysis and deposition of the crystals
in renal tubules (uric acid nephropathy). The use of nephro-
toxic agents like intravenous contrasts agents, nonsteroidal
anti-inﬂammatory drugs, nephrotoxic antibiotics and drugs
thatinhibituricacidsecretion(thiazides,andaspirin)should
be avoided.
STLS is not as common in solid tumors compared to
hematologic malignancies, but we believe that it might be an
underdiagnosed entity, as many cases of mild grade TLS with
less deranged abnormalities in the laboratory parameters
can be missed easily. The patients with above risk factors
should be treated prophylactically with aggressive hydration
and uricolytic agents before the initiation of chemotherapy.
Our case highlights the criticality of identifying STLS in solidCase Reports in Medicine 3
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tumors with big tumor burden and treating prophylactically
to prevent this cataclysmic syndrome.
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